Data reported here is for acute HCV infections among individuals aged 18-40, which serves as a proxy for the rate of new HCV infections among people who inject drugs (PWID) per year, one of the primary HCV elimination metrics for New York State.
The increase in acute hepatitis C (HCV) infections in 2024 in New York State and New York City was driven in large part by NYC’s implementation of laboratory reporting of negative HCV antibody results in 2024, which improved the detection of acute HCV identified via HCV antibody seroconversion in NYC.
Data source: Hepatitis Elimination and Epidemiology Dataset (HEED), as of January 2025.
Data reported here is for acute HCV infections among individuals aged 18-40, which serves as a proxy for the rate of new HCV infections among people who inject drugs (PWID) per year, one of the primary HCV elimination metrics for New York State.
Annual targets are set based on achieving a linear 25% reduction in observed acute case rates from 2020 (baseline year) by 2025, and a linear 90% reduction in acute case rates from 2020 by 2030.
Targets only available for new infection rates per 100,000, not actual counts.
